title: Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Torjesen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D006801:Humans; D007267:Injections; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab; D013222:State Medicine / Q000191:economics; D016896:Treatment Outcome; D006113:United Kingdom; D014792:Visual Acuity / Q000187:drug effects; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab